Literature DB >> 17030651

Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.

David A Lewis1, Bita Moghaddam.   

Abstract

Impairments in certain cognitive functions mediated by the dorsolateral prefrontal cortex, such as working memory, are core features of schizophrenia. Convergent findings suggest that these disturbances are associated with alterations in markers of inhibitory gamma-aminobutyric acid and excitatory glutamate neurotransmission in the dorsolateral prefrontal cortex. Specifically, reduced gamma-aminobutyric acid synthesis is present in the subpopulation of gamma-aminobutyric acid neurons that express the calcium-binding protein parvalbumin. Despite presynaptic and postsynaptic compensatory responses, the resulting impaired inhibitory regulation of pyramidal neurons contributes to a reduction in the synchronized neuronal activity that is required for working memory function. Several lines of evidence suggest that these changes may be either secondary to or exacerbated by impaired signaling via the N-methyl-d-aspartate class of glutamate receptors. These findings suggest specific targets for therapeutic interventions to improve cognitive function in individuals with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17030651     DOI: 10.1001/archneur.63.10.1372

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  184 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Quantitation of parvalbumin+ neurons and human immunodeficiency virus type 1 (HIV-1) regulatory gene expression in the HIV-1 transgenic rat: effects of vitamin A deficiency and morphine.

Authors:  Shireen Sultana; Huifen Li; Adam Puche; Odell Jones; Joseph L Bryant; Walter Royal
Journal:  J Neurovirol       Date:  2010-02       Impact factor: 2.643

4.  Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia.

Authors:  L V Kristiansen; B Bakir; V Haroutunian; J H Meador-Woodruff
Journal:  Schizophr Res       Date:  2010-03-29       Impact factor: 4.939

5.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Ikwunga Wonodi; Rosalinda C Roberts; Arash Rassoulpour; Robert P McMahon; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-10-29       Impact factor: 9.306

Review 6.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

Review 7.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

Review 8.  Biomarkers in psychosis: an approach to early identification and individualized treatment.

Authors:  Heline Mirzakhanian; Fiza Singh; Kristin S Cadenhead
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

Review 9.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

10.  Increased hippocampal, thalamic, and prefrontal hemodynamic response to an urban noise stimulus in schizophrenia.

Authors:  Jason R Tregellas; Jamey Ellis; Shireen Shatti; Yiping P Du; Donald C Rojas
Journal:  Am J Psychiatry       Date:  2009-01-15       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.